MediMix Oncology
  • Home
  • Congresses
    • 2025
      • ASCO 2025
      • ASCO GI 2025
      • ENETS 2025
      • ELCC 2025
      • EADO 2025
    • 2024
      • SABCS 2024
      • ESMO 2024
      • ESMO GI 2024
      • ASCO 2024
      • JFHOD 2024
      • ASCO GU 2024
      • ESGO & SGO 2024
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
Breast CancerSABCS 2023

Results from UPTIDER

6 December 2023

In this poster, Dr Karen Van Baelen, a Researcher PhD student at the University Hospitals Leuven in Belgium, presented results from the post-mortem tissue donation program UPTIDER on the metastatic spread in patients with lobular breast cancer.  

This poster conducted examinations through autopsies on six patients, revealing valuable insights into various aspects of the disease.

One significant revelation involved the identification of previously unseen metastases, constituting approximately one-fourth of the observed metastatic lesions. Despite the macroscopic normalcy of the organ, microscopic examination exposed complete infiltration by lobular breast cancer cells. The examination of histopathological features facilitated a correlation between primary and metastatic lesions.

Consistent analysis of E-cadherin expression indicated its absence or aberration in all lesions, reinforcing the classification of lobular breast cancer. Tumour-Infiltrating Lymphocytes analysis revealed a relatively low presence in the metastatic lesions. Remarkably, the ER status was found to be maintained in a significant proportion of metastases, even in cases where endocrine treatment was no longer effective. In contrast, PR status exhibited variation, with only 42% of metastases retaining the same PR status as the primary tumour.

These findings underscore the importance of the UPTIDER program and its lobular breast cancer sub-study, highlighting often overlooked aspects of metastases. Clinicians are urged to consider potential disease progression even in the absence of apparent imaging abnormalities. The correlation between primary and metastatic samples offers valuable insights, particularly regarding the persistence of ER status.

Reference:

Van Baelen K. et al., Underestimation of metastatic spread in patients with lobular breast cancer: results from the post-mortem tissue donation program UPTIDER – SABCS 2023, #P01-06-06

You may also be interested in:

CDK4/6 inhibition in metastatic ILC versus NST BC: comparison of PFS and OS

8 December 2023

Impact of breast cancer therapy on vaginal health and sexuality

8 December 2023

DESTINY-Breast15

7 December 2023

With the educational support of:

Tags:

poster

Share Article

Website created by MediMix © 2025 - Privacy Policy

  • Home
  • Congresses
    • 2025
      • ASCO 2025
      • ASCO GI 2025
      • ENETS 2025
      • ELCC 2025
      • EADO 2025
    • 2024
      • SABCS 2024
      • ESMO 2024
      • ESMO GI 2024
      • ASCO 2024
      • JFHOD 2024
      • ASCO GU 2024
      • ESGO & SGO 2024
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok